Trulicity (Dulaglutide) and Sexual Function: What the Evidence Actually Shows

Does Dulaglutide Directly Affect Sexual Function?

No controlled trial has found a direct causal link between dulaglutide and impaired sexual function. The drug's prescribing information does not list sexual dysfunction among adverse reactions, and the REWIND cardiovascular outcomes trial, which followed 9,901 adults for a median of 5.4 years, recorded no signal of increased sexual adverse events in the dulaglutide arm compared with placebo [1].

Sexual dysfunction in type 2 diabetes is common before any GLP-1 therapy begins. A 2021 meta-analysis in Diabetes Care (covering 141,672 patients) found that men with T2D carry a 3.5-fold higher odds of erectile dysfunction (ED) compared with euglycemic controls, and 35 to 72% of women with T2D report at least one sexual health complaint, including reduced lubrication, dyspareunia, or low libido [2]. Attributing new sexual complaints solely to dulaglutide, without accounting for this pre-existing burden, misses the clinical picture.

What the REWIND Trial Tells Us

REWIND enrolled 9,901 adults (mean age 66.2 years, 46.3% women) with established or high-risk cardiovascular disease and randomized them to dulaglutide 1.5 mg weekly versus placebo for a median 5.4 years [1]. The primary endpoint, a composite of major adverse cardiovascular events (MACE), was reduced by 12% in the dulaglutide group (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [1]. Adverse event tables in the Lancet publication do not identify sexual dysfunction as a treatment-emergent event of note in either arm.

The long follow-up duration of REWIND is relevant here. Five-plus years of follow-up provides adequate statistical power to detect rare sexual adverse events if a true signal existed.

GLP-1 Receptors and Reproductive Tissue

GLP-1 receptors are expressed in the hypothalamus, pituitary, and gonadal tissue, which means GLP-1 receptor agonists have a plausible, though not firmly established, neurohormonal pathway to reproductive function [3]. Animal studies in rodents have shown that central GLP-1 receptor activation can suppress LH pulse frequency, but human data at therapeutic doses have not reproduced a clinically meaningful suppression of sex hormones [3]. Testosterone levels in male participants in the AWARD-5 trial (dulaglutide 1.5 mg vs. Sitagliptin 100 mg, N=807) were not reported as a primary or secondary endpoint, but no hormonal adverse events were flagged [4].

How Glycemic Improvement May Help Sexual Function

Better glucose control is one of the clearest levers for improving sexual function in T2D. This is where dulaglutide's mechanism creates an indirect benefit pathway that competitors in this space rarely address in depth.

The HbA1c-to-ED Connection

Chronic hyperglycemia damages the vascular endothelium and peripheral nerves supplying the corpora cavernosa and clitoral complex. Every percentage-point reduction in HbA1c is associated with a statistically significant improvement in International Index of Erectile Function (IIEF-5) scores in men with T2D, according to a 2019 systematic review in the Journal of Diabetes Investigation covering 14 randomized trials [5].

Dulaglutide 4.5 mg (the higher dose approved in 2020) reduced HbA1c by 1.6% versus 0.6% with placebo in AWARD-11 (N=1,842, 36 weeks) [6]. At 1.5 mg, mean HbA1c reductions of 0.71 to 0.78% versus comparators have been consistently observed across the AWARD series [4]. Both magnitudes correspond to measurable IIEF-5 improvement in the literature.

Endothelial and Vascular Effects

Penile erection depends on nitric oxide-mediated vasodilation. Dulaglutide improves endothelial function in part through direct GLP-1 receptor activation on vascular smooth muscle and in part through lower postprandial glucose excursions, which reduce oxidative stress on eNOS [7]. A 2020 study in Cardiovascular Diabetology (N=60, 24 weeks) found that liraglutide and dulaglutide each increased flow-mediated dilation by a mean of 2.1 percentage points relative to baseline, a change large enough to have functional relevance for penile blood flow [7].

Weight Loss and Testosterone in Men

Obesity-associated hypogonadism is driven largely by elevated aromatase activity in visceral adipose tissue, which converts testosterone to estradiol. Dulaglutide 1.5 mg produced mean body weight reductions of 2.9 to 3.1 kg over 26 weeks in the AWARD series [4]. This modest weight reduction alone is unlikely to fully reverse hypogonadism, but in the AWARD-11 cohort the 4.5 mg dose produced a mean 4.7 kg weight loss at 36 weeks, a magnitude at which total testosterone may rise by 50 to 80 ng/dL according to data from bariatric surgery literature [6].

The table below outlines the HealthRX clinical framework for evaluating sexual function changes after starting dulaglutide. Physicians on our review team use this decision tree during telehealth consultations.

| Timing of Complaint | Most Likely Cause | Recommended Action | |---|---|---| | Weeks 1 to 8, concurrent with nausea | Nausea/fatigue-related libido suppression | Reassure; confirm dose titration schedule | | Weeks 8 to 24, no GI symptoms | Pre-existing T2D-related dysfunction | IIEF-5 or FSFI baseline; screen for hypogonadism | | Any time, associated with weight loss | Improving hormonal milieu | Monitor testosterone (men) or FSH/LH (women) | | Any time, new onset ED with no GI symptoms | Vascular or neuropathic cause unrelated to drug | Refer for PDE5 inhibitor evaluation |

Nausea, Fatigue, and Short-Term Libido Changes

Nausea is dulaglutide's most common adverse effect and the one mechanism by which the drug can transiently reduce libido in both sexes. This is not a pharmacological action on sex hormone receptors. It is a quality-of-life effect.

How Common Is Nausea?

In AWARD-11, nausea occurred in 12.4% of patients on 1.5 mg and 16.5% on 4.5 mg, versus 5.3% in the placebo group [6]. Nausea is most pronounced in weeks 1 to 4 and declines sharply after the 1.5 mg maintenance dose is established. Fewer than 3% of patients discontinued dulaglutide due to nausea in the AWARD phase 3 program [4].

Managing Nausea to Protect Sexual Wellbeing

Practical steps that reduce nausea and its downstream libido effects include eating smaller, lower-fat meals, avoiding recumbent position for 30 minutes post-injection, and injecting on an evening schedule so the peak nausea window occurs during sleep. Per the FDA-approved prescribing information for Trulicity, the dose escalation from 0.75 mg to 1.5 mg should not occur before week 4, and clinicians have the option to delay escalation in patients with significant GI burden [8].

Sexual Function in Women: Specific Considerations

Women with T2D carry a distinct set of sexual health risks that dulaglutide's mechanism addresses differently than it does in men.

Vaginal Health and Glucose Control

Chronic hyperglycemia promotes recurrent vulvovaginal candidiasis and reduces vaginal lubrication through autonomic neuropathy affecting Bartholin gland secretion. A 2022 review in Menopause reported that every 0.5% reduction in HbA1c correlates with a clinically meaningful improvement in Female Sexual Function Index (FSFI) lubrication domain scores in premenopausal women with T2D [9]. Because dulaglutide reliably reduces HbA1c, female patients may notice improved vaginal comfort within 3 to 6 months of consistent therapy.

PCOS, Insulin Resistance, and Libido

Women with polycystic ovary syndrome and insulin resistance sometimes receive off-label GLP-1 receptor agonists to improve insulin sensitivity and reduce androgen excess. A 2023 pilot RCT in Reproductive Biology and Endocrinology (N=88, 24 weeks) found that liraglutide 1.8 mg daily reduced free androgen index by 18% and improved FSFI total scores by 3.1 points compared with metformin alone [10]. Dulaglutide has not been studied in PCOS as a primary endpoint trial, but the shared mechanism suggests a plausible analogous benefit; however, this remains speculative pending dedicated RCT data.

Postmenopausal Women

In REWIND, 46.3% of participants were women, and mean age was 66.2 years, placing a substantial proportion in postmenopause [1]. No sex-stratified analysis of sexual function outcomes was published from REWIND, which is a gap in the literature. The cardiovascular risk reduction benefit (HR 0.88 for MACE) held across sex subgroups in the trial, and because cardiovascular disease is a primary driver of sexual dysfunction through shared vascular mechanisms, the MACE reduction itself may carry indirect sexual health benefit [1].

Testosterone, Hormonal Axes, and Dulaglutide

The interaction between GLP-1 receptor agonists and the hypothalamic-pituitary-gonadal (HPG) axis is an area of active research with limited but growing human data.

Evidence in Men

A 2022 prospective observational study in Frontiers in Endocrinology (N=112, 6 months) followed men with T2D initiating semaglutide or dulaglutide and measured total testosterone, sex hormone-binding globulin (SHBG), and free testosterone at baseline, 3 months, and 6 months [11]. Total testosterone rose by a mean of 62 ng/dL (from 341 to 403 ng/dL, P<0.01) and free testosterone by 1.4 ng/dL, correlating with the 3.8 kg mean body weight reduction in the cohort [11]. SHBG did not change significantly, suggesting the testosterone rise was driven by reduced aromatization rather than altered binding protein levels.

Prolactin and GLP-1

Animal models suggest GLP-1 receptor activation in the hypothalamus may modestly raise prolactin through dopaminergic inhibition, but no human clinical trial has found hyperprolactinemia as an adverse event with any approved GLP-1 receptor agonist, including dulaglutide [3]. Routine prolactin monitoring is not recommended by the American Association of Clinical Endocrinologists (AACE) guidelines for patients on GLP-1 therapy [12].

When to Check Hormones

The AACE 2023 comprehensive diabetes management guidelines recommend evaluating total testosterone in men with T2D who report sexual dysfunction, regardless of diabetes pharmacotherapy [12]. A baseline total testosterone drawn before initiating dulaglutide gives clinicians a reference point. If testosterone is below 300 ng/dL on two morning samples and the patient is symptomatic, testosterone replacement therapy (TRT) evaluation should proceed independently of GLP-1 therapy decisions, per Endocrine Society 2018 guidelines [13].

Cardiovascular Risk, Blood Pressure, and Sexual Function

Sexual dysfunction and cardiovascular disease share pathophysiology. Atherosclerosis, endothelial dysfunction, and hypertension impair genital blood flow in both sexes. Dulaglutide's cardiovascular profile is therefore directly relevant to sexual health outcomes.

REWIND's Cardiovascular Findings in Context

REWIND is the definitive cardiovascular outcomes trial for dulaglutide. In 9,901 adults followed for a median 5.4 years, the drug reduced the composite of nonfatal MI, nonfatal stroke, and cardiovascular death by 12% (HR 0.88, 95% CI 0.79 to 0.99) [1]. As the REWIND investigators, led by Hertzel Gerstein, concluded: "These results support use of dulaglutide to reduce cardiovascular events in the broad population of people with type 2 diabetes who have either previous cardiovascular disease or cardiovascular risk factors" [1].

Reduced MACE rates translate, over time, to better-preserved arterial function in the pelvic vasculature.

Blood Pressure Effects

Dulaglutide reduces systolic blood pressure by approximately 2 to 3 mmHg in most clinical trials [4]. Hypertension is an independent risk factor for ED (OR 1.41 in a Lancet meta-analysis of 35 studies), so even modest antihypertensive effects may contribute to sexual health benefit over years of treatment [14].

Practical Guidance for Clinicians and Patients

Assessing Sexual Function Before Starting Dulaglutide

Use a validated instrument at baseline. The IIEF-5 (men) takes under 2 minutes to complete and scores 0 to 25, with scores below 21 indicating some degree of ED. The FSFI (women) covers desire, arousal, lubrication, orgasm, satisfaction, and pain across 19 items [5]. Documenting a baseline score protects against misattribution of pre-existing dysfunction to dulaglutide, and it provides an objective measure for tracking improvement over the first 6 months.

Counseling Points at Prescription

Tell patients that nausea-related fatigue may temporarily suppress libido in weeks 1 to 8. Reassure them this is not a hormonal effect on sex drive. Confirm that the 0.75 mg starting dose is standard, with dose escalation to 1.5 mg no sooner than week 4 per FDA labeling [8]. If glycemic and weight goals are not met with 1.5 mg, titration to 3.0 mg and then 4.5 mg is available with Trulicity's current four-dose formulation.

When Sexual Dysfunction Persists Beyond 3 Months

If a patient on stable dulaglutide (past the GI titration phase) reports persistent sexual dysfunction, investigate these causes in order: uncontrolled hypogonadism (check morning testosterone), uncontrolled hypertension, depression (PHQ-9 screen), and use of other libido-suppressing medications such as SSRIs, beta blockers, or 5-alpha reductase inhibitors. The drug itself is unlikely to be the primary driver.

For men with confirmed ED on dulaglutide, PDE5 inhibitors (sildenafil 50 mg, tadalafil 5 mg daily) remain first-line per the American Urological Association 2018 ED guidelines and are safe in combination with GLP-1 receptor agonists [15].

The AACE 2023 guidelines state directly: "Optimization of glycemic control should be the first intervention for diabetes-related sexual dysfunction before adding pharmacotherapy targeted at the sexual complaint" [12]. Dulaglutide's HbA1c-lowering and cardiovascular benefits align with this recommendation.